<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00838877</url>
  </required_header>
  <id_info>
    <org_study_id>D2750C00001</org_study_id>
    <secondary_id>2008-006747-39</secondary_id>
    <nct_id>NCT00838877</nct_id>
  </id_info>
  <brief_title>Positron Emission Tomography (PET) Study With [18F]AZD4694 and [11C]AZD2184, Candidate PET Ligands for Aβ Amyloid</brief_title>
  <acronym>PET</acronym>
  <official_title>Open Label Positron Emission Tomography Study With [18F]AZD4694 and [11C]AZD2184, Candidate Radioligands for AB Amyloid, to Determine and Compare in Vivo Brain Uptake and Distribution in Healthy Volunteers and Patients With Alzheimer's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is carried out in order to investigate if [18F]AZD4694, compared to [11C]AZD2184,
      is a suitable PET ligand for in vivo imaging of Aβ amyloid depositions in the human brain. In
      the study the two PET ligands will be examined in both healthy volunteers and patients with
      Alzheimer's Disease. A whole body dosimetry scanning will be performed in 6 healthy
      volunteers to obtain human data to estimate a safe dose.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positron emission tomography using the radioligand [18F]AZD4694 and/or [11C]AZD2184</measure>
    <time_frame>Radioligand [18F]AZD4694: 1-2 PET examinations for AD patients and 1 PET examination for healthy volunteers. Whole body dosimetri for some healthy volunteers. - Radioligand [11C]AZD2184: 1 PET for AD patients respective healthy volunteers.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess safety and tolerability of [18F]AZD4694 and the study procedures, by assessment of adverse events, vital signs, and laboratory variables.</measure>
    <time_frame>3-4 visits with tests for AD patients respective healthy volunteers. All tests are not done at every visit.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">26</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radioligand [18F]AZD4694</intervention_name>
    <description>single dose of iv. admin. 1-2 times per subject</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>radioligand [11C]AZD2184</intervention_name>
    <description>single dose of iv admin. 1 time per subject</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Alzheimer's Disease patients - 50-85 years, mild to moderate AD: MMSE ≥16 and ≤ 26,
             clinical progression of AD over 12 months.

          -  Healthy volunteers: - 50-75 years

          -  BMI 18 and 30 m2/kg

          -  Clinically normal physical findings including supine blood pressure and pulse rate.

        Exclusion Criteria:

          -  Alzheimer's Disease patients - Clinically significant illness the 2 weeks prior to the
             administration of the PET ligand

          -  Significant cerebrovascular disease or depression, central nervous system infarct or
             infection or lesions

          -  Administration of any investigational product within 3 months prior to study and/or
             PET measurements for scientific purposes within the last 12 months.

          -  Healthy volunteers - clinically significant illness within 2 weeks before
             administration of PET ligand, history of psychiatric or somatic disease/condition that
             may interfere, first degree relative with dementia. Obvious deterioration of memory
             functions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria E Jönhagen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Geriatric Clinic, Karolinska University Hospital, Huddinge, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ingemar Bylesjö</last_name>
    <role>Principal Investigator</role>
    <affiliation>AstraZeneca Clinical Pharmacology Unit, Stockholm</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Julin</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca R&amp;D, Södertälje, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huddinge</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 6, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2009</study_first_posted>
  <last_update_submitted>October 21, 2009</last_update_submitted>
  <last_update_submitted_qc>October 21, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 23, 2009</last_update_posted>
  <responsible_party>
    <name_title>Björn Paulsson, MD, Medical Science Director, AD &amp; Cognition</name_title>
    <organization>AstraZeneca R&amp;D Södertälje, Sweden</organization>
  </responsible_party>
  <keyword>Alzheimer's Disease</keyword>
  <keyword>PET</keyword>
  <keyword>Phase 1</keyword>
  <keyword>Positron Emission Tomography</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

